Literature DB >> 11513749

c-Jun N-terminal kinase-interacting protein 1 inhibits gene expression in response to hypertrophic agonists in neonatal rat ventricular myocytes.

S G Finn1, M Dickens, S J Fuller.   

Abstract

G(q)-coupled receptor agonists, such as endothelin-1 (ET-1) and phenylephrine (PE), initiate a hypertrophic response in cardiac myocytes that is characterized by increased expression of atrial natriuretic factor (ANF), beta-myosin heavy chain (beta-MHC), skeletal muscle alpha-actin (SkalphaA) and ventricular myosin light chain-2 (vMLC2). ET-1 and PE activate both the extracellular signal-regulated kinases and c-Jun N-terminal kinases (JNKs) in cardiac myocytes, but the extent to which each contributes to the hypertrophic response is uncertain. Here we have used the JNK-binding domain of JNK-interacting protein 1 (JIP-1), a cytosolic scaffold protein that binds to JNK and inhibits its signalling when overexpressed, to assess the contribution of JNK activation to the hypertrophic response. Expression of JIP-1 inhibited the increase in ANF, beta-MHC, SkalphaA and vMLC2 reporter gene expression in response to ET-1 (by 45-86%) and PE (by 56-60%). However, activation of these reporter genes by PMA, which does not activate JNK significantly in myocytes, was much less affected by overexpression of JIP-1. JIP-1 also failed to inhibit reporter gene activation in response to constitutively active Ras or Raf, but attenuated reporter gene activation induced by a constitutively active mutant of mitogen-activated protein kinase kinase kinase 1 (MEKK1), an upstream kinase that preferentially activates JNKs, by 50%. Overexpression of JIP-1 also significantly reduced the increase in cell area in response to PE from 63% to 56%, but had no effect on the increase in cell size in response to ET-1 (38%). These results suggest that activation of the JNK pathway contributes to the transcriptional and morphological responses to G(q) receptor-coupled hypertrophic agonists.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513749      PMCID: PMC1222083          DOI: 10.1042/0264-6021:3580489

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

1.  Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells.

Authors:  Y Wang; B Su; V P Sah; J H Brown; J Han; K R Chien
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

2.  Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes.

Authors:  G R Post; D Goldstein; D J Thuerauf; C C Glembotski; J H Brown
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

3.  A cytoplasmic inhibitor of the JNK signal transduction pathway.

Authors:  M Dickens; J S Rogers; J Cavanagh; A Raitano; Z Xia; J R Halpern; M E Greenberg; C L Sawyers; R J Davis
Journal:  Science       Date:  1997-08-01       Impact factor: 47.728

4.  Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes.

Authors:  S J Fuller; E L Davies; J Gillespie-Brown; H Sun; N K Tonks
Journal:  Biochem J       Date:  1997-04-15       Impact factor: 3.857

5.  The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy.

Authors:  M T Ramirez; V P Sah; X L Zhao; J J Hunter; K R Chien; J H Brown
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

6.  Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family.

Authors:  Y Wang; S Huang; V P Sah; J Ross; J H Brown; J Han; K R Chien
Journal:  J Biol Chem       Date:  1998-01-23       Impact factor: 5.157

Review 7.  Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion.

Authors:  M A Bogoyevitch; J Gillespie-Brown; A J Ketterman; S J Fuller; R Ben-Levy; A Ashworth; C J Marshall; P H Sugden
Journal:  Circ Res       Date:  1996-08       Impact factor: 17.367

8.  Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways.

Authors:  V P Sah; M Hoshijima; K R Chien; J H Brown
Journal:  J Biol Chem       Date:  1996-12-06       Impact factor: 5.157

9.  Inhibition of a signaling pathway in cardiac muscle cells by active mitogen-activated protein kinase kinase.

Authors:  J Thorburn; M Carlson; S J Mansour; K R Chien; N G Ahn; A Thorburn
Journal:  Mol Biol Cell       Date:  1995-11       Impact factor: 4.138

10.  A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression.

Authors:  D Zechner; D J Thuerauf; D S Hanford; P M McDonough; C C Glembotski
Journal:  J Cell Biol       Date:  1997-10-06       Impact factor: 10.539

View more
  10 in total

1.  AFos dissociates cardiac myocyte hypertrophy and expression of the pathological gene program.

Authors:  Mark Y Jeong; Koichiro Kinugawa; Charles Vinson; Carlin S Long
Journal:  Circulation       Date:  2005-03-28       Impact factor: 29.690

Review 2.  RSK3: A regulator of pathological cardiac remodeling.

Authors:  Eliana C Martinez; Catherine L Passariello; Jinliang Li; Christopher J Matheson; Kimberly Dodge-Kafka; Philip Reigan; Michael S Kapiloff
Journal:  IUBMB Life       Date:  2015-05-19       Impact factor: 3.885

3.  Role of apoptosis signal-regulating kinase-1-c-Jun NH2-terminal kinase-p38 signaling in voltage-gated K+ channel remodeling of the failing heart: regulation by thioredoxin.

Authors:  Kang Tang; Xun Li; Ming-Qi Zheng; George J Rozanski
Journal:  Antioxid Redox Signal       Date:  2010-08-30       Impact factor: 8.401

Review 4.  Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology.

Authors:  Tána Ravingerová; Miroslav Barancík; Monika Strnisková
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

5.  Chronic activation of extracellular-signal-regulated protein kinases by phenylephrine is required to elicit a hypertrophic response in cardiac myocytes.

Authors:  Anthony J Barron; Stephen G Finn; Stephen J Fuller
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

6.  Class I HDACs control a JIP1-dependent pathway for kinesin-microtubule binding in cardiomyocytes.

Authors:  Weston W Blakeslee; Ying-Hsi Lin; Matthew S Stratton; Philip D Tatman; Tianjing Hu; Bradley S Ferguson; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2017-09-05       Impact factor: 5.000

7.  Activation of ASK1, downstream MAPKK and MAPK isoforms during cardiac ischaemia.

Authors:  Stephen J Harding; Gareth J Browne; Bryan W Miller; Sally A Prigent; Martin Dickens
Journal:  Biochim Biophys Acta       Date:  2010-06-13

Review 8.  Transcription factors in heart: promising therapeutic targets in cardiac hypertrophy.

Authors:  Shrey Kohli; Suchit Ahuja; Vibha Rani
Journal:  Curr Cardiol Rev       Date:  2011-11

9.  Transcriptional and Post-Translational Targeting of Myocyte Stress Protein 1 (MS1) by the JNK Pathway in Cardiac Myocytes.

Authors:  Joanna M Hay; Eva S Jordan; Gareth J Browne; Andrew R Bottrill; Sally A Prigent; Martin Dickens
Journal:  J Mol Signal       Date:  2017-12-08

10.  Targeting the Nrf2/ARE Signalling Pathway to Mitigate Isoproterenol-Induced Cardiac Hypertrophy: Plausible Role of Hesperetin in Redox Homeostasis.

Authors:  Prema Velusamy; Thangarajeswari Mohan; Divya Bhavani Ravi; S N Kishore Kumar; Ashokkumar Srinivasan; Lakshmi Narasimhan Chakrapani; Abhilasha Singh; Saradhadevi Varadharaj; Periandavan Kalaiselvi
Journal:  Oxid Med Cell Longev       Date:  2020-09-01       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.